Free tool
FAERS Monitor: Elfabrio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761161 or its brand name (Elfabrio, Pegunigalsidase Alfa-Iwxj). Reports on generic versions are filed under their own applications.
Reports
377
Serious
159
42% of reports
Hospitalization
77
Death reported
13
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue37
- off label use34
- product dose omission issue27
- pain26
- nausea25
- ill-defined disorder19
- infusion related reaction17
- pyrexia17
- vomiting16
- asthenia13
- chills13
- condition aggravated12
- pain in extremity12
- product administration interrupted12
- chest pain11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2023 | 11 |
| 2024 | 111 |
| 2025 | 130 |
| 2026 | 124 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,782 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product administration interruptedSignal | 12 | 85.4 | 48.9 | 918 |
| ill-defined disorderSignal | 19 | 17.5 | 11.3 | 279 |
| infusion related reactionSignal | 17 | 14.3 | 9.0 | 198 |
| chillsSignal | 13 | 6.2 | 3.6 | 52 |
| product dose omission issueSignal | 27 | 5.1 | 3.6 | 87 |
| chest painSignal | 11 | 3.3 | 1.9 | 16 |
| pyrexiaSignal | 17 | 2.7 | 1.7 | 17 |
| fatigueSignal | 37 | 2.7 | 2.0 | 38 |
| painSignal | 26 | 2.4 | 1.6 | 20 |
| pain in extremitySignal | 12 | 2.3 | 1.3 | 7 |
| condition aggravatedSignal | 12 | 2.2 | 1.3 | 7 |
| off label useSignal | 34 | 2.2 | 1.6 | 21 |
| asthenia | 13 | 1.9 | 1.1 | 5 |
| vomiting | 16 | 1.9 | 1.2 | 6 |
| nausea | 25 | 1.8 | 1.2 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.